# De-escalating Antiplatelet Therapy to Assess Platelet Reactivity and Outcomes in High Bleeding Risk Patients With Recent ACS

Study · id `cardio:ct-nct05903976` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05903976](<https://clinicaltrials.gov/study/NCT05903976>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05903976

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT05903976. Randomized; no masking; primary purpose treatment. Start 2023-06-12 (actual); primary completion 2025-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT05903976, source copy `cardio:ctgov-nct05903976-2023-08-23`, retrieved 2026-10-26)
- Started: 2023-06-12 (actual) (ClinicalTrials.gov record NCT05903976, source copy `cardio:ctgov-nct05903976-2023-08-23`, retrieved 2026-10-26)
- Primary completion: 2025-06-30 (anticipated) (ClinicalTrials.gov record NCT05903976, source copy `cardio:ctgov-nct05903976-2023-08-23`, retrieved 2026-10-26)
- Completion: 2025-10-30 (anticipated) (ClinicalTrials.gov record NCT05903976, source copy `cardio:ctgov-nct05903976-2023-08-23`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT05903976, source copy `cardio:ctgov-nct05903976-2023-08-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05903976-2023-08-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: De-escalating Antiplatelet Therapy to Assess Platelet Reactivity and Outcomes in High Bleeding Risk Patients With Recent ACS
- Acronym: DESC-HBR
- Condition: Dual Antiplatelet Therapy
- Condition: Acute Coronary Syndrome
- Condition: Coronary Artery Disease
- Intervention (Drug): P2Y12 inhibitor de-escalation
- Lead sponsor: Azienda Ospedaliera Universitaria Policlinico "G. Martino"
- Lead sponsor class: OTHER
- Collaborator: Giampiero Vizzari
- Collaborator class: UNKNOWN
- Collaborator: Giorgio Quadri
- Collaborator class: UNKNOWN
- Collaborator: Greca Zanda
- Collaborator class: UNKNOWN
- Collaborator: Ferdinando Varbella
- Collaborator class: UNKNOWN
- Collaborator: Gianluca Di Bella
- Collaborator class: UNKNOWN
- Collaborator: Antonio Micari
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)

## Provenance

Content hash: dd7036a7d88633c6d6a7687f7f25db2983f954f28a22b056aa6af584c1b1c526
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
